US COVID-19 Fraud: After Facebook Posts, Regulators Don’t ‘Friend’ ChromaDex
Executive Summary
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.
You may also be interested in...
Window Of Opportunity Opened Narrowly For Continued Use Of NAC As Dietary Ingredient In US
FDA will “determine if rulemaking to make NAC lawful as a dietary supplement is appropriate.” Agency issued tentative responses to Council for Responsible Nutrition and Natural Products Association’s petitions asking for halt to warnings and other enforcement against firms marketing supplements containing NAC.
Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease
DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.
ChromaDex Loss Down, Tru Niagen Sales Up 22%
Q3 net sales were up 18% and its net loss dropped $3m, the provider of Tru Niagen products containing Niagen, its proprietary form of nicotinamide riboside, reported five days before announcing Tru Niagen stick packs are available under the EX brand in Hong Kong exclusively at A.S. Watson Group’s stores and website.